Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MULTIVITAMINS

All products: not a benefit

Pregvit · DIN 02451573 · · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.Discontinued 2025-03-07 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pregvit · DIN 02451573 Manufacturer: Duchesnay Inc.; listing date 2025-02-28 Health Canada: Cancelled post market since 2025-03-07 · brand PREGVIT · ATC B03AE04 IRON, MULTIVITAMINS AND MINERALS · form Tablet · route Oral · ingredients ASCORBIC ACID (ASCORBIC ACID) 120 MG, VITAMIN D3 (CHOLECALCIFEROL) 600 UNIT, BETA-CAROTENE 1.6 MG, NICOTINAMIDE 20 MG, FOLIC ACID 1.1 MG, VITAMIN B1 (THIAMINE MONONITRATE) 3 MG, ZINC (ZINC OXIDE) 15 MG, VITAMIN B12 (CYANOCOBALAMIN) 12 MCG, MAGNESIUM (MAGNESIUM OXIDE) 50 MG, VITAMIN B2 (RIBOFLAVIN) 3.4 MG, VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG, VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE) 13.8 MG, COPPER (CUPRIC OXIDE) 2 MG, D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 5 MG, IRON (FERROUS FUMARATE) 35 MG, CALCIUM (CALCIUM CARBONATE) 300 MG, IODINE (POTASSIUM IODIDE) 0.15 MG · company Duchesnay inc · schedule Prescription
Check this DIN again · Health Canada product record

Pregvit: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93788 · Verify on the e-Formulary ↗ (DIN 02451573)

Source record
DIN 02451573: Pregvit Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 882800066; group id 889; item number 2135; lccId None; manufacturer id DUI Source form: Tab; strength: None Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02451573 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93788
Interchangeable products
Pregnancy Multivitamin · DIN 02535718 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02451573
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-03-07 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (88:28 Multivitamins) and how they are covered

Matched class: 88:28 Multivitamins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MULTIVITAMINS FOR INFUSION 88:28 Multivitamins

MULTIVITAMINS FOR INFUSION

· 2 products · General benefit · strengths: · Inj-2x5mL Vial Pk, Inj-4mL+1mL Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 88:28
Full class listing Related classes: 88:08 Vitamin B, 88:12 Vitamin C, 88:16 Vitamin D Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Other review policies

For Pregvit: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026